Epothilones - Hope for patients not susceptible to treatment with taxanes;Epotilony - Nadzieja dla pacjentów niewrażliwych na leczenie taksanami

Wspolczesna Onkologia

Volumn 14, Issue 3, 2010, Pages 205-210

  Rogalska, Aneta ^a   Marczak, Agnieszka ^a   Szwed, Marzena ^a   Gajek, Arkadiusz ^a   Jóźwiak, Zofia ^a  

^a UNIVERSITY OF LODZ   (Poland)

Author keywords

Anthracyclines; Epothilones; Mechanisms of action; Microtubules; Taxanes

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CAPECITABINE; CARBOPLATIN; DOCETAXEL; EPOTHILONE A; EPOTHILONE B; EPOTHILONE C; EPOTHILONE D; EPOTHILONE DERIVATIVE; FLUOROURACIL; IXABEPILONE; PACLITAXEL; SAGOPILONE; TAXANE DERIVATIVE; TRASTUZUMAB; UNCLASSIFIED DRUG; ZK 219447;

ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER CLASSIFICATION; CANCER PATIENT; CHEMICAL STRUCTURE; CLINICAL RESEARCH; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; HUMAN; LUNG NON SMALL CELL CANCER; NEOPLASM; NONHUMAN; REVIEW; TREATMENT INDICATION;

EID: 77954361052     PISSN: 14282526     EISSN: 14282526     Source Type: Journal    
DOI: 10.5114/wo.2010.14131     Document Type: Review

References (40)

1. Lee JJ, Swain SM. The epothilones: translating from the laboratory to the clinic. Clin Cancer Res 2008; 14: 1618-24.
2. Cheng KL, Bradley T, Budman DR. Novel microtubule-targeting agents - the epothilones. Biologics 2008; 2: 789-811.
3. Fojo T, Menefee M. Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents. Ann Oncol 2007; 18: 3-8.
4. Beumer JH, Garner RC, Cohen MB, Galbraith S, Duncan GF, Griffin T, Beijnen JH, Schellens JH. Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry. Invest New Drugs 2007; 25: 327-34. (Pubitemid 46944849)
5. Altmann KH, Hüsken D, Cuenoud B, García-Echeverría C. Synthesis and hybridization properties of polyamide based nucleic acid analogues incorporating pyrrolidine-derived nucleoamino acids. Bioorg Med Chem Lett 2000; 10: 929-33. (Pubitemid 30301596)
6. Goodin S. Novel cytotoxic agents: Epothiones. Am J Health-Syst Pharm 2008; 65: 10-15.
7. Thomas ES, Gomez HL, Li RK, Chung HC, Fein LE, Chan VF, Jassem J, Pivot XB, et. al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007; 25: 5210-7.
8. Egerton N. Ixabepilone (ixempra), a therapeutic option for locally advanced or metastatic breast cancer. P T 2008; 33: 523-31.
9. Steinberg M. Ixabepilone: a novel microtubule inhibitor for the treatment of locally advanced or metastatic breast cancer. Clin Ther 2008; 30: 1590-617.
10. Mok TS, Choi E, Yau D, Johri A, Yeo W, Chan AT, Wong C. Effects of patupilone (epothilone B; EPO906), a novel chemotherapeutic agent, in hepatocellular carcinoma: an in vitro study. Oncology 2006; 71: 292-6.
11. Moulder SL, Arteaga CL. A Phase I/II Trial of trastuzumab and gefitinib in patients with Metastatic Breast Cancer that overexpresses HER2/neu (ErbB-2). Clin Breast Cancer 2003; 4: 142-5.
12. Gradishar W. Management of advanced breast cancer with the epothilone B analog, ixabepilone. Drug Des Devel Ther 2009; 3: 163-71.
13. Załuska J, Prochowska E, Karczewska-Dzionk A, Załuski J, Wysocki PJ. Kapecytabina w monoterapii u chorych z uogólnionym rakiem piersi - obserwacje własne na tle danych literaturowych. Współcz Onkol 2008; 12: 384-7.
14. Pignata S, De Placido S, Biamonte R, et. al. Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the multicenter italian trial in ovarian cancer (MITO-4) retrospective study. BMC Cancer 2006; 7: 1-7
15. Edelman MJ. Novel taxane formulations and microtubule-binding agents in non-small-cell lung cancer. Clin Lung Cancer 2009; 10: 30-4.
16. Cardoso F, de Azambuja E, Lago LD. Current perspectives of epothilones in breast cancer. Eur J Cancer 2008; 44: 341-52.
17. Hoffmann J, Vitale I, Buchmann B, et. al. Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone. Cancer Res 2008; 68: 5301-8.
18. Hoffmann J, Fichtner I, Lemm M, Lienau P, Hess-Stumpp H, Rotgeri A, Hofmann B, Klar U. Sagopilone crosses the blood-brain barrier in vivo to inhibit brain tumor growth and metastases. Neuro Oncol 2009; 11: 158-66.
19. Lee SH, Son SM, Son DJ, et. al. Epothilones induce human colon cancer SW620 cell apoptosis via the tubulin polymerization independent activation of the nuclear factor-kappaB/IkappaB kinase signal pathway. Mol Cancer Ther 2007; 6: 2786-97.
20. Goodin S, Kane MP, Rubin EH. Epothilones: mechanism of action and biologic activity. J Clin Oncol 2004; 22: 2015-25. (Pubitemid 41095195)
21. Yamaguchi H, Chen J, Bhalla K, Wang HG. Regulation of Bax activation and apoptotic response to microtubule-damaging agents by p53 transcription-dependent and independent pathways. J Biol Chem 2004; 279: 39431-7.
22. Burger H, Foekens JA, Look MP, Meijer-van Gelder ME, Klijn JG, Wiemer EA, Stoter G, Nooter K. RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response. Clin Cancer Res 2003; 9: 827-36. (Pubitemid 36182621)
23. Griffin D, Wittmann S, Guo F, Nimmanapalli R, Bali P, Wang HG, Bhalla K. Molecular determinants of epothilone B derivative (BMS 247550) and Apo-2L/TRAIL-induced apoptosis of human ovarian cancer cells. Gynecol Oncol 2003; 89: 37-47. (Pubitemid 36403645)
24. Khawaja NR, Carré M, Kovacic H, Estève MA, Braguer D. Patupilone-induced apoptosis is mediated by mitochondrial reactive oxygen species through Bim relocalization to mitochondria. Mol Pharmacol 2008; 74: 1072-83.
25. Grosicki S, Grosicka A. Hołowiecki J. Kliniczne znaczenie angiogenezy i czynników ja̧ modyfikuja̧cych w onkohematologii. Wiadomości Lekarskie 2007; 1-2: 39-46.
26. Bijman MN, van Nieuw Amerongen GP, Laurens N, van Hinsbergh VW, Boven E. Microtubule-targeting agents inhibit angiogenesis at subtoxic concentrations, a process associated with inhibition of Rac1 and Cdc42 activity and changes in the endothelial cytoskeleton. Mol Cancer Ther 2006; 5: 2348-57. (Pubitemid 44530472)
27. Chiorazzi A, Nicolini G, Canta A, et. al. Experimental epothilone B neurotoxicity: results of in vitro and in vivo studies. Neurobiol Dis 2009; 35: 270-7.
28. Quick QA. Epothilone B induces glioblastoma cell death via survivin down-regulation. Exp Oncol 2008; 30: 195-201.
29. Moreno-Aspitia A, Perez EA. Anthracycline- and/or taxane-resistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends. Clin Ther 2009; 31: 1619-40.
30. Sharom F.J. ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics 2008; 9: 105-27.
31. Bergstralh DT, Taxman DJ, Chou TC, Danishefsky SJ, Ting JP. A comparison of signaling activities induced by Taxol and desoxyepothilone B. J Chemother 2004; 16: 563-76.
32. Lee FY, Covello KL, Castaneda S, Hawken DR, Kan D, Lewin A, Wen ML, Ryseck RP, et. al. Synergistic antitumor activity of ixabepilone (BMS-247550) plus bevacizumab in multiple in vivo tumor models. Clin Cancer Res 2008; 14: 8123-31.
33. Lee FY, Borzilleri R, Fairchild CR, Kamath A, Smykla R, Kramer R, Vite G. Preclinical discovery of ixabepilone, a highly active antineoplastic agent. Cancer Chemother Pharmacol 2008; 63: 157-66.
34. Hofstetter B, Vuong V, Broggini-Tenzer A, et. al. Patupilone acts as radiosensitizing agent in multidrug-resistant cancer cells in vitro and in vivo. Clin Cancer Res 2005; 11: 1588-96.
35. Mani S, Huang H, Sundarababu S, Liu W, Kalpana G, Smith AB, Horwitz SB. Activation of the steroid and xenobiotic receptor (human pregnane X receptor) by nontaxane microtubule-stabilizing agents. Clin Cancer Res 2005; 11: 6359-69. (Pubitemid 41262968)
36. Hopper-Borge E, Xu X, Shen T, Shi Z, Chen Z, Kruh GD. Human multidrug resistance protein 7 (ABCC10) is a resistance factor for nucleoside analogues and epothilone B. Cancer Res 2009; 69: 178-84.
37. Brunden KR, Trojanowski JQ, Lee VM. Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies. Nat Rev Drug Discov 2009; 8: 783-93.
38. Wittmann S, Bali P, Donapaty S, et. al. Flavopiridol down-regulates antiapoptotic proteins and sensitizes human breast cancer cells to 9 epothilone B-induced apoptosis. Cancer Res 2003; 63: 93-9.
39. Pfeiffer B, Hauenstein K, Merz P, Gertsch J, Altmann KH. Synthesis and SAR of C12-C13-oxazoline derivatives of epothilone A. Bioorg Med Chem Lett 2009; 19: 3760-3.
40. Wang J, Zhang H, Ying L, Wang C, Jiang N, Zhou Y, Wang H, Bai H. Five new epothilone metabolites from Sorangium cellulosum strain So0157-2. J Antibiot 2009; 62: 483-7.